TY - JOUR
T1 - Prevention and Management of Osteoradionecrosis in Patients With Head and Neck Cancer Treated With Radiation Therapy
T2 - ISOO-MASCC-ASCO Guideline
AU - Peterson, Douglas E
AU - Koyfman, Shlomo A
AU - Yarom, Noam
AU - Lynggaard, Charlotte Duch
AU - Ismaila, Nofisat
AU - Forner, Lone E
AU - Fuller, Clifton David
AU - Mowery, Yvonne M
AU - Murphy, Barbara A
AU - Watson, Erin
AU - Yang, David H
AU - Alajbeg, Ivan
AU - Bossi, Paolo
AU - Fritz, Michael
AU - Futran, Neal D
AU - Gelblum, Daphna Y
AU - King, Edward
AU - Ruggiero, Salvatore
AU - Smith, Derek K
AU - Villa, Alessandro
AU - Wu, Jonn S
AU - Saunders, Deborah
PY - 2024/6/1
Y1 - 2024/6/1
N2 - PURPOSE: To provide evidence-based recommendations for prevention and management of osteoradionecrosis (ORN) of the jaw secondary to head and neck radiation therapy in patients with cancer.METHODS: The International Society of Oral Oncology-Multinational Association for Supportive Care in Cancer (ISOO-MASCC) and ASCO convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. PubMed, EMBASE, and Cochrane Library databases were searched for randomized controlled trials and observational studies, published between January 1, 2009, and December 1, 2023. The guideline also incorporated systematic reviews conducted by ISOO-MASCC, which included studies published from January 1, 1990, through December 31, 2008.RESULTS: A total of 1,539 publications were initially identified. There were 487 duplicate publications, resulting in 1,052 studies screened by abstract, 104 screened by full text, and 80 included for systematic review evaluation.RECOMMENDATIONS: Due to limitations of available evidence, the guideline relied on informal consensus for some recommendations. Recommendations that were deemed evidence-based with strong evidence by the Expert Panel were those pertaining to best practices in prevention of ORN and surgical management. No recommendation was possible for the utilization of leukocyte- and platelet-rich fibrin or photobiomodulation for prevention of ORN. The use of hyperbaric oxygen in prevention and management of ORN remains largely unjustified, with limited evidence to support its practice.Additional information is available at www.asco.org/head-neck-cancer-guidelines.
AB - PURPOSE: To provide evidence-based recommendations for prevention and management of osteoradionecrosis (ORN) of the jaw secondary to head and neck radiation therapy in patients with cancer.METHODS: The International Society of Oral Oncology-Multinational Association for Supportive Care in Cancer (ISOO-MASCC) and ASCO convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. PubMed, EMBASE, and Cochrane Library databases were searched for randomized controlled trials and observational studies, published between January 1, 2009, and December 1, 2023. The guideline also incorporated systematic reviews conducted by ISOO-MASCC, which included studies published from January 1, 1990, through December 31, 2008.RESULTS: A total of 1,539 publications were initially identified. There were 487 duplicate publications, resulting in 1,052 studies screened by abstract, 104 screened by full text, and 80 included for systematic review evaluation.RECOMMENDATIONS: Due to limitations of available evidence, the guideline relied on informal consensus for some recommendations. Recommendations that were deemed evidence-based with strong evidence by the Expert Panel were those pertaining to best practices in prevention of ORN and surgical management. No recommendation was possible for the utilization of leukocyte- and platelet-rich fibrin or photobiomodulation for prevention of ORN. The use of hyperbaric oxygen in prevention and management of ORN remains largely unjustified, with limited evidence to support its practice.Additional information is available at www.asco.org/head-neck-cancer-guidelines.
KW - Head and Neck Neoplasms/radiotherapy
KW - Humans
KW - Osteoradionecrosis/prevention & control
UR - http://www.scopus.com/inward/record.url?scp=85194202930&partnerID=8YFLogxK
U2 - 10.1200/JCO.23.02750
DO - 10.1200/JCO.23.02750
M3 - Journal article
C2 - 38691821
SN - 0732-183X
VL - 42
SP - 1975
EP - 1996
JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
IS - 16
ER -